Paper Details

  1. Home
  2. Paper Details

Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.

Author: AntinoriSpinello, BorghiVanni, CicculloArturo, D'EttorreGabriella, De VitoAndrea, Di GiambenedettoSimona, DucciFilippo, GiacomelliAndrea, GiacomettiAndrea, LagiFilippo, MadedduGiordano, MussiniCristina, PincinoRachele, SterrantinoGaetana, TaramassoLucia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The study compared dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) regimens in virologically suppressed people living with HIV (PLWHIV) who switched from a standard three-drug regimen. Both regimens had low discontinuation rates and virologic failure rates, with toxicity being the most common reason for discontinuation. No significant differences were observed in CD4 cell counts, lipid parameters, or renal function between the two groups.
Paper Details　
Original Abstract of the Article :
Real-life comparisons of dolutegravir/rilpivirine (DTG/RPV) and DTG/lamivudine (3TC) regimens in people living with human immunodeficiency virus (PLWHIV) who switched from a standard three-drug regimen based on nonnucleoside reverse transcriptase inhibitors (NNRTIs) are missing. This study aimed to ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/jmv.29149

データ提供：米国国立医学図書館（NLM）

Dolutegravir-Based Regimens for HIV Treatment

HIV treatment is a continuous journey through a vast and complex desert, requiring constant vigilance and adaptation. This study examines the efficacy and tolerability of two dolutegravir-based regimens in patients transitioning from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). The researchers compared dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) regimens in a real-world setting.

Dolutegravir-Based Regimens: Navigating the HIV Treatment Desert

The researchers found that both DTG/3TC and DTG/RPV regimens demonstrated low discontinuation rates and virological failure rates in patients transitioning from NNRTI-based therapy. These findings suggest that both regimens are effective options for transitioning patients, offering a stable path through the challenging desert of HIV management. The researchers also found that both regimens were well-tolerated, with similar adverse event profiles. This suggests that both regimens are suitable options for patients transitioning from NNRTI-based therapy.

Finding the Right Path: Navigating the HIV Treatment Desert

This research provides valuable insights for clinicians managing HIV-infected patients. The findings highlight the effectiveness and tolerability of dolutegravir-based regimens, offering clinicians a reliable tool for transitioning patients to simpler, two-drug regimens. It's like finding a well-maintained path through the desert of HIV treatment, leading to sustained viral suppression and improved quality of life for patients.

Dr.Camel's Conclusion

This real-world study demonstrates the effectiveness and tolerability of dolutegravir-based regimens for transitioning patients from NNRTI-based therapy. These findings provide valuable insights for clinicians, offering a reliable and well-tolerated path through the desert of HIV treatment, leading to sustained viral suppression and improved quality of life for patients.

Date :
  1. Date Completed 2023-10-09
  2. Date Revised 2023-10-18
Further Info :

Pubmed ID

37805832

DOI: Digital Object Identifier

10.1002/jmv.29149

Related Literature

Article Analysis
・Effects of dolutegravir and lamivudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.